Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients

Basit Öğe Kaydı
dc.contributor.authorAnadolu, Rana Yavuzer
dc.contributor.authorBirol, Ahu
dc.contributor.authorŞanlı, Hatice
dc.contributor.authorErdem, Cengizhan
dc.contributor.authorTürsen, Ümit
dc.date.accessioned2020-06-25T17:40:33Z
dc.date.available2020-06-25T17:40:33Z
dc.date.issued2005
dc.departmentKırıkkale Üniversitesi
dc.descriptionErdem, Cengizhan/0000-0002-9312-5683; tursen, umit/0000-0002-5807-6759
dc.description.abstractBackground Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common forms of cutaneous T-cell lymphoma (CTCL). Various topical and systemic therapeutic alternatives are available, but there is no standard or definite curative treatment regimen. When making a decision about the appropriate treatment modality, the age and compliance of the patient, stage of the disease, treatment accessibility, and previous treatment history should be considered. Aim To determine the therapeutic response of patients with MF and SS to different treatment modalities. Patients were evaluated with respect to their clinical and demographic features. Methods One hundred and thirteen patients diagnosed clinically and dermatopathologically with MF and SS between March 1984 and June 2001 were included in the study. Results Of the 113 patients studied, 110 had a diagnosis of MF and three had a diagnosis of SS; 101 patients (89.4%) were diagnosed with early stage (IA, IB, IIA) and 12 (10.6%) with late stage (IIB, III, IVA, IVB) disease. The age at diagnosis varied between 12 and 81 years (mean, 45.6 +/- 15.8 years). Fifty-five (48.7%) patients were male and 58 (51.3%) were female. The duration of the skin lesions varied between 1.5 months and 32 years (mean, 6.1 years). Psoralen plus UVA (PUVA) was the most commonly used initial treatment modality in early stage disease (91%), with a complete remission (CR) rate of 80.4%. With PUVA + interferon-alpha (INF-alpha) treatment, CR was 57% in the early stages and 33.3% in the late stages. For late stage disease, systemic therapies, such as pentostatin, gemcitabine, and fludarabine, alone or in combination with INF-alpha, were preferred. Of the 113 patients, eight (7% of the total and 57.1% of the advanced stage cases) died of MF; 21.4% of the late stage patients showed partial remission and 14.2% showed CR. None of the patients diagnosed with early stage disease died of MF, but two (1.9%) progressed to late stage disease. Conclusions PUVA and PUVA + INF-alpha are effective treatment modalities, especially for early stage MF. Once the disease has progressed, both MF and SS are very resistant to treatment regimens, including chemotherapeutic agents. It is important to diagnose and treat these diseases, especially MF, in the early stages for lasting remission.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1111/j.1365-4632.2004.02033.x
dc.identifier.endpage565en_US
dc.identifier.issn0011-9059
dc.identifier.issn1365-4632
dc.identifier.issue7en_US
dc.identifier.pmid15985024
dc.identifier.scopus2-s2.0-21844472754
dc.identifier.scopusqualityQ1
dc.identifier.startpage559en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-4632.2004.02033.x
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3480
dc.identifier.volume44en_US
dc.identifier.wosWOS:000230143000006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal Of Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleMycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patientsen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Mycosis fungoides and Sezary syndrome therapeutic approach and outcome in 113 patients.pdf
Boyut:
100.21 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu